-

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China
Abstract: This retrospective study aimed to delineate the utilization trends of autologous hematopoietic stem cell transplantation (AHSCT) for lymphoma and multiple myeloma (MM) in China, utilizing data from 211 AHSCT…
-

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma
Study Design: The research employed a comprehensive approach, encompassing both in vitro and in vivo evaluations. In vitro assessments involved exposing tFL cells to varying concentrations of anlotinib, measuring cell…
-

Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study
Study Design: This observational cohort study, conducted at the First Affiliated Hospital of Soochow University, aimed to assess the impact of the Omicron variant of SARS-CoV-2 on allo-hematopoietic stem cell…
-
The Complex Impact of CMV Reactivation Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comprehensive Review
Introduction: Allogeneic hematopoietic stem cell transplantation stands as a cornerstone treatment for hematologic malignancies, yet the specter of CMV reactivation looms large, threatening the well-being of transplant recipients. CMV reactivation,…
-

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL). However, despite its remarkable efficacy, a subset of patients experiences…
-

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives
Introduction: The introduction of chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has undeniably transformed the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, a persistent…

